These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 12189224

  • 1. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group.
    J Natl Cancer Inst; 2002 Aug 21; 94(16):1211-20. PubMed ID: 12189224
    [Abstract] [Full Text] [Related]

  • 2. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
    Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG.
    J Natl Cancer Inst; 2006 Feb 15; 98(4):273-84. PubMed ID: 16478746
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
    Vansteenkiste J, Poulsen E, Rossi G, Glaspy J.
    Oncology (Williston Park); 2002 Oct 15; 16(10 Suppl 11):45-55. PubMed ID: 12435173
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
    Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C.
    J Thorac Oncol; 2020 Feb 15; 15(2):190-202. PubMed ID: 31629060
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.
    Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF.
    J Clin Oncol; 2008 May 10; 26(14):2342-9. PubMed ID: 18467726
    [Abstract] [Full Text] [Related]

  • 8. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline.
    Vansteenkiste J, Tomita D, Rossi G, Pirker R.
    Support Care Cancer; 2004 Apr 10; 12(4):253-62. PubMed ID: 14740283
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 10; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
    Ichinose Y, Seto T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K, Saijo N, Hotta T.
    Jpn J Clin Oncol; 2010 Jun 10; 40(6):521-9. PubMed ID: 20508073
    [Abstract] [Full Text] [Related]

  • 11. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 12. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct 03; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 13. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C.
    Oncologist; 2008 Jun 03; 13(6):715-24. PubMed ID: 18586927
    [Abstract] [Full Text] [Related]

  • 14. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
    Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, Schuette W.
    Clin Lung Cancer; 2011 Jan 03; 12(1):62-9. PubMed ID: 21273182
    [Abstract] [Full Text] [Related]

  • 15. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 03; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 16. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
    Cases A.
    Drugs Today (Barc); 2003 Jul 03; 39(7):477-95. PubMed ID: 12973399
    [Abstract] [Full Text] [Related]

  • 17. Re: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    VanAudenrode M.
    J Natl Cancer Inst; 2003 May 21; 95(10):761-2; author reply 762-3. PubMed ID: 12759400
    [No Abstract] [Full Text] [Related]

  • 18. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 May 21; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 19. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group.
    J Clin Oncol; 2001 Jun 01; 19(11):2865-74. PubMed ID: 11387359
    [Abstract] [Full Text] [Related]

  • 20. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K.
    Curr Med Res Opin; 2007 Jun 01; 23(6):1387-401. PubMed ID: 17559735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.